Immunotherapy After Transplantation for Skin Cancer Prevention in Organ

Status Not yet recruiting

Clinical Trial Summary

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

Clinical Trial Description

The main goal of this investigator-initiated clinical trial is to determine the efficacy of topical calcipotriol combined with 5-fluorouracil (5-FU) treatment in OTRs on immunosuppressive medications with precancerous skin lesions called actinic keratoses (AKs) and a history of non-melanoma skin cancer in order to eliminate AKs and prevent squamous cell carcinoma (SCC) development. SCC is the most common cutaneous malignancy seen after transplantation, with a 65-250fold greater incidence in organ transplant recipients (OTRs) compared to the general population. This increased risk is due to the systemic immunosuppression caused by anti-rejection medications, which are indispensable for protecting against allograft loss. Our previous findings have established the efficacy of calcipotriol in combination with 5-FU in inducing an antitumor immunity against AKs in immunocompetent patients. This SCC risk reduction is accompanied by the induction of robust T cell immunity and TRM cell formation against AKs. Calcipotriol is a FDA-approved low calcemic vitamin D analogue for the treatment of psoriasis. Topical 5-FU is a standard chemotherapy for AKs. Based on our previous findings demonstrating the synergistic impact of TSLP induction by calcipotriol in combination with the cytotoxic effects of 5-FU that leads to a robust T cell immunity against early skin carcinogenesis in immunocompetent patients, we aim to determine whether this efficacy is maintained in OTRs on immunosuppressive therapy and its effect on SCC prevention in long-term after transplantation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04642287
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Shadmehr Demehri, MD/ PHD
Phone	617-643-6436
Email	sdemehri1@mgh.harvard.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	January 2026
Completion date	January 2030

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02721459` - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	Phase 1
Completed	`NCT03740815` - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection	N/A
Recruiting	`NCT05779423` - Cryoablation+Ipilimumab+Nivolumab in Melanoma	Phase 2
Terminated	`NCT01468818` - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma	Phase 2
Completed	`NCT01820234` - Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event	N/A
Completed	`NCT00535769` - Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use	Phase 0
Completed	`NCT00526032` - Melanoma Detection by Oblique-Incidence Optical Spectroscopy	N/A
Completed	`NCT00588341` - Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection	Phase 2
Active, not recruiting	`NCT01447199` - The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Enrolling by invitation	`NCT04758988` - AI Augmented Training for Skin Specialists	N/A
Not yet recruiting	`NCT04534868` - Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area	N/A
Recruiting	`NCT04138342` - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	Phase 1
Completed	`NCT03673917` - Cosmetology Students and Skin Cancer	N/A
Recruiting	`NCT04341064` - Sun-safe Habits Intervention and Education	Phase 3
Completed	`NCT04206995` - Cancer Sensing: Evaluation of Odour Sampling Techniques
Recruiting	`NCT05574101` - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer	Phase 2
Not yet recruiting	`NCT05860881` - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)	Phase 3
Completed	`NCT05146622` - Virtual Sun Safe Workplaces Ph I
Recruiting	`NCT05068310` - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Recruiting	`NCT03889899` - Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms